Lakewood-Amedex Biotherapeutics Inc. Common Stock (LABT) - Net Assets
Based on the latest financial reports, Lakewood-Amedex Biotherapeutics Inc. Common Stock (LABT) has net assets worth $-2.84 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($196.34K) and total liabilities ($3.04 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore LABT net asset momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-2.84 Million |
| % of Total Assets | -1447.29% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 244.3 |
Lakewood-Amedex Biotherapeutics Inc. Common Stock - Net Assets Trend (2023–2025)
This chart illustrates how Lakewood-Amedex Biotherapeutics Inc. Common Stock's net assets have evolved over time, based on quarterly financial data. See LABT net asset quality score to measure how much of total assets are equity-financed.
Annual Net Assets for Lakewood-Amedex Biotherapeutics Inc. Common Stock (2023–2025)
The table below shows the annual net assets of Lakewood-Amedex Biotherapeutics Inc. Common Stock from 2023 to 2025. For live market cap and overall valuation, see how much is Lakewood-Amedex Biotherapeutics Inc. Com worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $-1.96 Million | -579.61% |
| 2024-12-31 | $409.61K | -91.01% |
| 2023-12-31 | $4.56 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Lakewood-Amedex Biotherapeutics Inc. Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 870304200.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $51.39 Million | % |
| Total Equity | $-1.96 Million | 100.00% |
Lakewood-Amedex Biotherapeutics Inc. Common Stock Competitors by Market Cap
The table below lists competitors of Lakewood-Amedex Biotherapeutics Inc. Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Odyssean Investment Trust PLC
LSE:OIT
|
$3.89 Million |
|
Mustang Bio Inc
NASDAQ:MBIO
|
$3.90 Million |
|
New Plus Knitting Public Company Limited
BK:NPK
|
$3.90 Million |
|
Octopus Renewables Infra Trust
LSE:ORIT
|
$3.90 Million |
|
Groupe Airwell Société anonyme
PA:ALAIR
|
$3.89 Million |
|
Bio-Gene Technology Ltd
AU:BGT
|
$3.89 Million |
|
Adherium Ltd
AU:ADR
|
$3.88 Million |
|
Sabre Resources Ltd
AU:SBR
|
$3.88 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Lakewood-Amedex Biotherapeutics Inc. Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 409,611 to -1,964,537, a change of -2,374,148 (-579.6%).
- Net loss of 3,847,637 reduced equity.
- Other factors increased equity by 1,473,489.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-3.85 Million | -195.85% |
| Other Changes | $1.47 Million | +75.0% |
| Total Change | $- | -579.61% |
Book Value vs Market Value Analysis
This analysis compares Lakewood-Amedex Biotherapeutics Inc. Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2023-12-31 | $3.27 | $2.24 | x |
| 2024-12-31 | $0.29 | $2.24 | x |
| 2025-12-31 | $-1.41 | $2.24 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Lakewood-Amedex Biotherapeutics Inc. Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-455.69%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2023 | -181.69% | 0.00% | 0.00x | 1.51x | $-8.74 Million |
| 2024 | -1185.37% | 0.00% | 0.00x | 2.61x | $-4.90 Million |
| 2025 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.65 Million |
Industry Comparison
This section compares Lakewood-Amedex Biotherapeutics Inc. Common Stock's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $151,234,733
- Average return on equity (ROE) among peers: -69.30%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Lakewood-Amedex Biotherapeutics Inc. Common Stock (LABT) | $-2.84 Million | -181.69% | N/A | $3.89 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $148.49 Million |
| Abcellera Biologics Inc (ABCL) | $1.03 Billion | -0.22% | 0.29x | $2.99 Billion |
| Abeona Therapeutics Inc (ABEO) | $4.82 Million | -556.02% | 2.44x | $335.61 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-11.42 Million | 0.00% | 0.00x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $-14.95 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $274.41 Million | -38.23% | 0.17x | $1.59 Billion |
| Arbutus Biopharma Corp (ABUS) | $136.85 Million | -50.75% | 0.43x | $906.70 Million |
| ABVC Biopharma Inc (ABVC) | $-1.46 Million | 0.00% | 0.00x | $23.14 Million |
| Abivax SA American Depositary Shares (ABVX) | $48.18 Million | -23.29% | 0.12x | $10.02 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $84.98 Million | -24.53% | 0.28x | $5.07 Billion |
About Lakewood-Amedex Biotherapeutics Inc. Common Stock
Lakewood-Amedex Biotherapeutics, Inc. operates as a clinical-stage biotechnology company that develops antimicrobial products in the United States. The company offers products from its Bisphosphocin class, a novel class of antimicrobial agents a broad range of infections, including those affecting the skin, bladder, and lungs. It also develops Nu-3, a topical antimicrobial for infected diabetic f… Read more